Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So interesting that they have reforumulated Anatabloc----
Hydrapharm Anatabloc 150 Capsules
Serving Size: 1 Capsule
Servings Per Container: 150
Amount Per Serving %DV**
Anatabine (as anatabine citrate) 2mg +
Vitamin A (as retinyl acetate) 90IU 3%
Vitamin D (as cholecalciferol) 40IU 7%
Other ingredients: Microcrystalline Cellulose, Gelatin (Capsule), Rice Flour, Magnesium Stearate.
DIRECTIONS FOR USE
Weight 45kg-55kg- 1 capsule 3 times per day
https://www.predatornutrition.com/hydrapharm/hydrapharm/anatabloc.html
BONO Brother What are you thoughts? Have you purchased Anatabloc?
I was told otherwise. Each of the 200 AC5 applications do not each require a separate human trial. I was told for example when they apply for their CE Mark they will include every external application under the sun. Does not mean they will all be approved.
Good point on shelf life. How about it can be stored at room temperature?
The Good Doc KSS is awesome !!
Doc
When you look at the Arch Company presentation page 26
https://content.equisolve.net/archtherapeutics/media/c6dc3c52a4e0458fae43779086460ea0.pdf
they show the Potential external applications for but a few of the 200+ applications for AC5
in JUST the USA:
Adhesions Opportunity $ 1 to $ 2 Billion
GI Sealant Opportunity $ .5 to $ 1 Billion
Burns Opportunity $ 1 Billion
Shown previously
Pressure Ulcers Opportunity $ 2 Billion (2.5 million people costing $ 10 Billion in USA)
Foot Ulcers Opportunity $ 1 to $ 2 Billion
These are not small target markets for external applications do you agree? BTW the profit margins are extremely high---extremely high !!
Do you follow Dr. KSS MD PHD? His PHD in in Molecular
Biology of Coagulation Regulation. Right in Arch's field !!
Short version $ARTH Elevator Pitch.
Arch Therapeutics –Symbol ARTH
Arch is a small public company with a medical device pathway, relatively low capital requirements and potentially high margin novel products targeting large growing markets.
· Company owns a product called AC5 with over 200 potential applications for controlling bleeding (hemostasis) and body leakage (sealant) during surgery, trauma care or wound care. Many of the 200 potential applications are addressing Billion $ markets. Arch is being called the “WD-40” of Biotech. Arch has a tiny market cap of approximately $ 100 million.
· A few of the potential applications for AC5 are Pressure Ulcers or Bedsores (USA 2.5 million patients a year), Diabetic Foot Ulcers (1-1.5 million patients in USA each year),Burn victims (500K patients per year in USA), etc.
· Scientists at Massachusetts Institute of Technology invented this universal fix-all hemostat that works in a few seconds as compared to competitor products that may take as long as minutes.
· CEO of Arch, Terrence Norchi, is a MD, MIT MBA and Former Portfolio Manager at Putnam’s $4 Billion Healthcare .
· AC5 is a clear liquid classified as a medical device. How is that possible? AC5 when applied has no metabolic or body interaction and acts merely as a physical mechanical barrier.
· As a medical device, not a drug, AC5 needs one clinical trial for approval in each market.
· AC5 is a noncoagulant hemostatic agent. There are no other noncoagulant hemostasis agents on the market. Thus AC5 works in the presence of BLOOD THINNERS! Only one that does.
· ARCH completed a very successful human clinical trial in Europe and will apply for the CE Mark and upon approval will be selling product in Europe in 2017 with a yet to be announced joint venture partner. Also in 2017 ARTH will complete a US trial and file for FDA approval.
· In 2015 Arch executed a research collaboration agreement with CÚRAM Centre for Research in Medical Devices in Galway, Ireland to deploy resources in Ireland to advance Arch’s technology, ranging from early stage research to late stage development and human clinical trials. For each one Euro that Arch contributes to an annual maximum of 250,000 € to its own R&D activities within CÚRAM, CÚRAM will contribute two Euros up to an annual maximum of €500,000 to those same activities, made possible by its grant funding from Science Foundation Ireland (SFI).
· Anytime a hole in the body occurs one needs to worry about bleeding, leaking and contamination to mitigate infection. Arch’s AC5 to address these needs. Arch intends to transform the landscape of interventional healthcare with products to seal and protect leaking and bleeding tissue.
· The clear liquid stops bleeding in SECONDS compared to minutes for most of the product’s competitors. The market for AC5 is unthinkably large: Every soldier in the world will need a bottle of AC5, every policeman in the world, every ambulance, every gun club, every ER in the world, every first aid kit in every office and manufacturing plant in the world, every person on blood thinners, etc.
· The Company’s product, AC5, a liquid peptide, should result in faster, safer, simpler surgery with substantial savings in time of surgery.
· AC5 is a disruptive technology with multiple uses in large market cap areas that has been proven to be very safe and very efficacious in human testing.
· There are many other hemostatic agents, but:
* They all rely on using the patient’s blood,
*They all take minutes to stop bleeding, not seconds
*None of them create a clear seal that a surgeon can see through
* None of them work just as well on people on blood thinners
* None of them work in every situation where bleeding has to be stopped
Arch’s AC5 product solves all these problems.
· Dr. KSS has called AC5 “possibly one of the best medicine inventions of all time…a noncoagulant hemostatic agent” and that the Company’s family of peptides “are truly among the most remarkable biochemical inventions of all time.”
· Arch’s successful human clinical study in Europe was conducted by Dr. Jack Kelly, Dr. Kelly, Principal Investigator of the human clinical study, and a plastic, reconstructive and aesthetic surgeon and Professor of Surgery at Galway University Hospital, Galway, Ireland, said, “These study results indicate significant potential for AC5 in the treatment of bleeding skin wounds. The safety and efficacy outcomes for AC5 in this study were impressive and reassuring. While possessing a safety profile at least as good as that of the control group, AC5 was associated with a clinically significant improvement in time to hemostasis. We are encouraged by how patients responded to the unique formulation of AC5 and how easy it was for a clinician to use.” Profile of Dr. Kelly http://jackkelly.ie/surgeon-profile
· Dr. Terrence Norchi the CEO of Arch comment regarding the AC5 +- 200 applications plus new potential product pipeline. “My view is that they’re all big, and there’s lots of them and that’s why we’re pretty excited.”
· Arch 2017 Planned Milestones 1) Submit and receive 510(k) for US commercialization FDA 2) File and receive CE Mark for EU commercialization 3) File IDE (Investigational Device Exemption) for internal surgical clinical trial 4) File additional patent applications 5) Establish commercialization strategy 6) Provide preclinical data on pipeline programs
· Top Manufacturers of Hemostasis Products
1) Johnson & Johnson
2) Abbott Laboratories
3) Baxter International Inc.
4) Becton Dickinson
5) CR Bard Inc.
6) CSL Behring LLC
7) Grifols Worldwide
LOL Right Dow up 25% since election.
What's a Safe Obesity Pill Worth? "There’s a gold mine available”- Bloomberg
https://www.bloomberg.com/news/articles/2017-07-04/why-big-pharma-is-struggling-to-profit-from-the-obesity-epidemic
$CWBR
Yes Hopefully sooner than later uplisting. Extremely important. The website is being revised.
Here is the near term CWBR catalyst
The company is set to make a presentation at The Liver Meeting 2017 slated for October 20-24, 2017 in Washington D.C.
Go look at page 16 slides in company presentation "CB4209 reduces Liver Fat
(Steatosis)--See slide 3
CohBar Vision and Background
www.cohbar.com
CWBR Elevator Summary tinyurl.com/y8pjbbra
Nice job Codaras !! Ready for an elevator pitch?
Promo Piece on Book- “Biggest investment opportunity in history.”
https://vimeo.com/234688381
Written by Jim Mellon (shareholder of CohBar) and Al Chalabi, distils extensive recent research into the science of longevity and also highlights the best opportunities for investors to capitalise on advances that have deep implications for all of our futures.
•Billionaire Jim Mellon Master Investor Show 2017—Investing in Longevity—“The New Money Fountain” Wrote new book on Longevity- Juvenescence: Investing in the age of Longevity
Starts at 28:30
45:00 MetFormin 45:15 Talked to Dr. Nir Barzilai 52:51 List of Longevity companies including CohBar 52:41 Shareholder of CohBar
Presentation
Thanks It is hard to hide. I am going to load up some other $ARTH things that will really help.
There is a comment search just below the article. Search $Welcome
Put in $ARTH it does it by page
or here
https://www.stockgumshoe.com/2017/09/is-aurinias-supremacy-in-lupus-nephritis-threatened-by-glaxos-benlysta/comment-page-2/#comment-4950597
Knowledge about your investment is powerful, All of biotech is high risk. Let's hope in this case with ARTH it is being removed as we go forward.
Agree. In the KSS conference call on ARCH I name 3 levels of prices IMHO and none of them are $12.....did low medium and high $ 3 $6 and $9
The longer the acquisition is delayed the closer we move to the high end.
Murphy even wrote an ebook on Arch available on Amazon. It was good but I did not learn much. It was just a confirmation.
Murphy came out with original ARTH article on seeking alpha in June 2015. I thought the article was an eye operner.
I just posted the references. Welcome. Enjoy and it will this forum even greater and on point !! Let's make a ton on $ARTH. We will need to start a new forum here for Doc's next new pick.
So their is a spreadsheet with all of Docs comments about every stock he has mentioned since 2014. It is the goldmine. I will post that also in an hour in the KSS Forum. I refer to it three time a week.
Agree. Dr. KSS has IMHO perfected his game. He is interviewing management with tough questions. He says he is working on a new pick.
I will repost the August 51 minute Arch discussion in Doc's forum in an hour. Plus September.
NNW Nice to see you post. You are dead on. He may just say forget it.
Did you become a shareholder of ARTH because of Dr. KSS or otherwise? Just curious.
I too will sorely miss him if he goes dark. We need to show our appreciation to him every way. I have learned sooooooo much. Everyday it is something new and exciting.
Following ARTH through his eyes has been amazing. His PHD is in coagulation.
Today he posted the cost of filing an IND with the FDA. I had no idea. I need to research and ask ARTH about.
To be clear you are saying you can access Doc's thread for free? Actually Travis has posted info on proprietary information.
Here is a email teaser I received from Newsletter writer Michael Murphy forecasting $12 a share for this company
Anyone recognize the company??? $ARTH
Company #2 - Bleeding is a huge problem, whether it is during surgery, at the scene of an accident, or on the battlefield. Much of the cost of an operation depends on how long it takes - the surgeon and support staff's time, and use of the expensive operating room. About 40% to 50% of operating time is spent controlling bleeding. An accident or battlefield injury can mean the victim bleeds out and dies before they can get to needed treatment.
What if a doctor or EMT could paint a clear liquid on any bleeding - even a spurting severed artery - and stop the bleeding in three to ten seconds? Leaving a clear film for observation and further surgery? And what if the FDA agreed to regulate that liquid as a device, with a faster and cheaper path to approval than a drug? What if the company only needed one clinical trial for approval? And the clinical trial is done and was successful?
That's the current position of Company #2. I expect FDA approval by the end of this year - maybe before Halloween. This is a $5 billion market in the US alone, plus probably another $5 billion in the rest of the world. Then there's the other 200 applications the company has identified - burns, diabetic ulcers, bed sores.... The stock sells for less than 80¢ a share with a market capitalization just over $100 million. Can it get to $2 billion and give you $20-for-$1? $2 billion for a dominant bleeding control product is nothing for a company like Johnson & Johnson that has several products in this area.
It was me. I know Dr. KSS well and have met him.. He works very very hard for paid subscribers as you well know.
What I have a problem with is taking proprietary information and posting it on the internet. As you know we have detailed information all the time about Arch. I have met Dr. Norchi also and have posted here for years. At Gumshoe we are very informed investors because of all the work that everyone puts in. We talked for 51 minutes on Arch in the August conference call in depth.
If you wish Dr. KSS to go into hiding for a select group keep up your posting of proprietary information. Please be fair to Dr. KSS. If you choose not to be I will call you out.
Dr. KSS has some stock picks that I believe are greater than $ARTH. Let him do his thing for paid subscribers.
Dr KSS has been following $ARTH since October 2014. My sincere hope is that everyone makes a ton on it.
Bono Watching the bid / ask. Most Chapter 7's emerge by one year and we are narrowing in on that.
Has Dr. KSS contacted you yet? I actually talked to him this morning and mentioned you. He asked to forward your postings about him.
That is proprietary information. Dr. KSS works too hard for you to be posting this all over the internet.
Newsletter Michael Murphy Target for $ARTH $12
You can now get the names and symbols for all five $20-for-$1 biotechs for less than $12 each through a monthly subscription to New World Investor. Just CLICK HERE.
Company #2 - Bleeding is a huge problem, whether it is during surgery, at the scene of an accident, or on the battlefield. Much of the cost of an operation depends on how long it takes - the surgeon and support staff's time, and use of the expensive operating room. About 40% to 50% of operating time is spent controlling bleeding. An accident or battlefield injury can mean the victim bleeds out and dies before they can get to needed treatment.
What if a doctor or EMT could paint a clear liquid on any bleeding - even a spurting severed artery - and stop the bleeding in three to ten seconds? Leaving a clear film for observation and further surgery? And what if the FDA agreed to regulate that liquid as a device, with a faster and cheaper path to approval than a drug? What if the company only needed one clinical trial for approval? And the clinical trial is done and was successful?
That's the current position of Company #2. I expect FDA approval by the end of this year - maybe before Halloween. This is a $5 billion market in the US alone, plus probably another $5 billion in the rest of the world. Then there's the other 200 applications the company has identified - burns, diabetic ulcers, bed sores.... The stock sells for less than 80¢ a share with a market capitalization just over $100 million. Can it get to $2 billion and give you $20-for-$1? $2 billion for a dominant bleeding control product is nothing for a company like Johnson & Johnson that has several products in this area.
I am just a CPA. And you know everything? Those are not GAAP numbers. Get real. I do consolidations for a living.
They are not consolidiated financial statements stated in accordance with GAAP. Therefore they are totally meaningless.
First of all you are not speaking from consolidated financial statements stated in accordance with GAAP. You are speaking from a 8-K which has no consolidated financial statements stated in accordance with GAAP. Those numbers are missing intracompany investments in RCP and Star. Rock Creek never ever had anywhere close to $ 83 million of consolidated debt.
For GAAP consolidated financial statements we have to look to June 30, 2016 which were filed with the SEC. At 6/30/16 the numbers were
$ 50,000 intellectual property Anatabloc
$ 10.4 M restricted cash only for long term debt
$ 15.4 long term debi
Net $ 5.0 M
Liabilities which go away
Payroll $ 4.2 M
Accounts Payable $5.0 M
Form 10-Q June 30, 2016
http://tinyurl.com/ya3q8tbo
http://yahoo.brand.edgar-online.com/default.aspx?cik=776008
I strongly suggest you understand GAAP accounting. When subsidiaries are consolidated it comes back to the numbers near the quarterly numbers. You have to eliminate intracompany payables.
You left out an important sentence.
Rock Creek Pharmaceuticals, Inc., together with its two wholly owned subsidiaries – RCP Development, Inc. and Star Tobacco, Inc. filed voluntary petitions under Chapter 7 of the United States Bankruptcy Code in the District of Delaware on September 27, 2016.
The case numbers are 16-12120, 16-12121 and 16-12123, respectively.
Rock Creek Pharmaceuticals, Inc. reported total assets of $35,139.15 and total liabilities of $21,300,999.35. RCP Development, Inc. reported total assets of $31,308.57 and total liabilities of $51,956,693.87 and Star Tobacco, Inc. reported total assets of $482,289.25 and total liabilities of $12,253,700.31.
They filed for 7 bankruptcy 9/28/16
I went through their last balance sheet 6/3016 filed
$ 50,000 intellectual property Anatabloc
$ 10.4 M restricted cash only for long term debt
$ 15.4 long term debi
Net $ 5.0 M
Liabilities which go away
Payroll $ 4.2 M
Accounts Payable $5.0 M
This looks so clean. $5.0 M debt to address----How difficult could this be??
Also six people control around 70% of stock. What's not to like? They went into Chapter 7 because of all the payroll nonsense from prior management.
Bono Can you see the train yet coming through the tunnel? Tough to buy a big block. One year is twenty days away.
Well ask Doc about his copyrighted material. That is what you should do. You are speaking to the choir since I have been around since October 2014. I know a thing or two about getting the word out.
Well I just checked and the 3 hours and 31 minutes is still there. I do not know how long it will be there.
$ARTH is discussed for 51 minutes of that.
1:42:26 to 2:19
AND
2:29:57 to 2:44 Dr. KSS addressing risk 2:41:15
Hi Tim We were going to have a conference call with Dr. Norchi but it has been delayed. This was covered on the thread a couple days ago by Glenn.
Hi Tim It is amazing how far behind this thread is. Posting copyrighted material from 2014 2015? Really. I think Dr. KSS is on it.
$49 total includes monthly conference call --In August spent 51 MINUTES on ARTH. Why be a mushroom? $ 49 ?
Oh and the pick that should Trump (no pun intended) $ARTH